Aytu BioScience, Inc., a specialty healthcare company focused on developing treatments for urological and related conditions, has acquired the rights to Primsol (trimethoprim hydrochloride) oral solution from FSC Laboratories, Inc.

Primsol is the company's second acquisition of a branded, revenue-generating product in the urology market, adding to its commercial-stage product portfolio, which also includes ProstaScint for the detection and assessment of prostate cancer.

Primsol is the only FDA-approved liquid formulation of trimethoprim, an antibiotic that is well established in current guidelines for treating uncomplicated urinary tract infections (UTIs). This differentiated product is appropriate for UTI patients that have difficulty swallowing tablets, such as the elderly, and particularly for patients that experience adverse reactions to sulfamethoxazole (sulfa).

Josh Disbrow, chief executive officer of Aytu BioScience, stated, "As we continue to build our commercial infrastructure over the next few months, we are excited to add a second established brand to our product portfolio. We expect to benefit from and continue to grow Primsol's established base of prescribers, which already includes a significant proportion of urologists despite the fact that it has not been previously marketed to these specialists. This allows us to utilize the same sales channel as ProstaScint, leading to potential commercial synergies. Aytu remains focused on executing on our core strategy of acquiring commercialized products and developing late-stage clinical assets while further expanding our leadership position in urology and related conditions. We are proud to bring Primsol to our core base of urology customers."

Aytu will pay a total of $1.75 million over the course of approximately 12 months, including an immediate $500,000 upfront payment. The Company will also purchase inventory valued at approximately $200,000 as part of the acquisition. The total acquisition cost represents only a slight premium to current gross annual sales of Primsol. All intellectual property and current manufacturing contracts will transfer to Aytu BioScience.

Primsol is an oral antibiotic containing trimethoprim hydrochloride that is indicated in adults for the treatment of initial episodes of uncomplicated urinary tract infections due to susceptible strains of the following organisms: Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae, Enterobacter species and coagulase-negative Staphylococcus species, including S. saprophyticus. Primsol is also indicated in pediatric patients for the treatment of acute otitis media due to susceptible strains of Streptococcus pneumoniae and Haemophilus influenzae.

The most commonly reported adverse reactions in paediatric clinical trials were: diarrhea, vomiting, skin rash, and abdominal pain.